Fly On The Wall
January 11, 2013
08:22 EDT CELG Celgene price target raised to $123 from $90 at Lazard Capital
Lazard Capital raised its price target for Celgene citing accelerating growth prospects after the company issued guidance earlier this week. The firm calls Celgene one of its top picks for 2013 and keeps a Buy rating on the name.